Amneal Pharmaceuticals, Inc. vs Travere Therapeutics, Inc.: Examining Key Revenue Metrics

Amneal vs. Travere: A Decade of Revenue Growth

__timestampAmneal Pharmaceuticals, Inc.Travere Therapeutics, Inc.
Wednesday, January 1, 201478562300028203205
Thursday, January 1, 201586628000099892000
Friday, January 1, 20161018225000133591000
Sunday, January 1, 20171033654000154937000
Monday, January 1, 20181662991000164246000
Tuesday, January 1, 20191626373000175338000
Wednesday, January 1, 20201992523000198321000
Friday, January 1, 20212093669000227490000
Saturday, January 1, 20222212304000212018000
Sunday, January 1, 20232393607000145238000
ngram

A Tale of Two Pharmaceuticals: Amneal vs. Travere

In the competitive landscape of pharmaceuticals, Amneal Pharmaceuticals, Inc. and Travere Therapeutics, Inc. have shown distinct revenue trajectories over the past decade. From 2014 to 2023, Amneal's revenue surged by over 200%, peaking at approximately $2.4 billion in 2023. This growth reflects a robust expansion strategy and successful product launches. In contrast, Travere's revenue, while growing, reached a more modest peak of around $227 million in 2021, before declining to $145 million in 2023. This represents a 400% increase from its 2014 figures, showcasing its niche focus and steady market penetration. The data highlights Amneal's dominance in scale, while Travere's growth underscores its strategic positioning in specialized markets. As the pharmaceutical industry evolves, these companies exemplify diverse paths to success, driven by innovation and market adaptation.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025